A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex

Arch Dermatol. 2012 Jan;148(1):138-9. doi: 10.1001/archderm.148.1.138.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Child
  • Child, Preschool
  • Humans
  • Hypopigmentation / drug therapy*
  • Hypopigmentation / etiology
  • Male
  • Sirolimus / administration & dosage*
  • TOR Serine-Threonine Kinases / antagonists & inhibitors*
  • Tuberous Sclerosis / complications

Substances

  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus